Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820

Investigational New Drugs

Volumn 27, Issue 2, 2009, Pages 140-152

  Keizer, Ron J ^a   Zamacona, Miren K ^b   Jansen, Mendel ^b   Critchley, David ^b   Wanders, Jantien ^b   Beijnen, Jos H ^a,d   Schellens, Jan H M ^c,d   Huitema, Alwin D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b EISAI CO LTD   (Japan)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Alpha2 integrin; E7820; Mixed effects modeling; Non compartmental analysis; Oncology; Population pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; E 7820; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; N (3 CYANO 4 METHYL 1H INDOL 7 YL) 3 CYANOBENZENE SULFONAMIDE; N-(3-CYANO-4-METHYL-1H-INDOL-7-YL)-3-CYANOBENZENE-SULFONAMIDE; SULFONAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED STUDY; DATA ANALYSIS; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FOOD INTAKE; HUMAN; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NONCOMPARTMENT MODEL; NONLINEAR SYSTEM; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; POPULATION PHARMACOKINETICS; PRIORITY JOURNAL; SOLID TUMOR; TECHNIQUE; TIME TO MAXIMUM PLASMA CONCENTRATION; BIOLOGICAL MODEL; COMPARATIVE STUDY; FOOD; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FOOD; HUMANS; INDOLES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SULFONAMIDES;

EID: 66949132213     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9164-x     Document Type: Article

References (30)

1. Y Funahashi 2002 Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium Cancer Res 62 6116 6123 (Pubitemid 35244460)
2. T Semba 2004 An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker Clin Cancer Res 10 1430 1438. (Pubitemid 38365238)
3. MJ Cross L Claesson-Welsh 2001 FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition Trends Pharmacol Sci 22 201 207 (Pubitemid 32244307)
4. GT Stavri 1995 Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia Circulation 92 11 14
5. DS Goodsell 2003 The molecular perspective: VEGF and angiogenesis Stem Cells 21 118 119 (Pubitemid 36120373)
6. MM Mita 2005 Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: results of a phase I study J Clin Oncol 23 3082
7. MM Mita 2006 Phase I study of an anti-angiogenic agent with a novel mechanism of action E7820: safety, pharmacokinetics (PK) and pharmacodynamic (PD) studies in patients (pts) with solid tumors J Clin Oncol 24 3048
8. FDA (1999) Guidance for industry: population pharmacokinetics.
9. F Guo SP Letrent A Sharma 2007 Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors Cancer Chemother Pharmacol 60 799 809 (Pubitemid 47389386)
10. CKK Lee 2006 Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue Clin Cancer Res 12 2158 2165
11. S Urien K Rezaí F Lokiec 2005 Pharmacokinetic modelling of 5-FU production from capecitabine-a population study in 40 adult patients with metastatic cancer J Pharmacokinet Pharmacodyn 32 817 833 (Pubitemid 41772359)
12. S Urien 2003 Phase I population pharmacokinetics of irofulven Anticancer Drugs 14 353 358 (Pubitemid 36683746)
13. C van Kesteren 2002 Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide) Br J Clin Pharmacol 54 463 471 (Pubitemid 35356871)
14. L Nguyen 2002 Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials Br J Clin Pharmacol 53 459 468 (Pubitemid 34526497)
15. M Crul 2002 Population pharmacokinetics of the novel anticancer agent KRN7000 Cancer Chemother Pharmacol 49 287 293 (Pubitemid 34253266)
16. P Tanswell 2001 Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients Br J Clin Pharmacol 51 177 180 (Pubitemid 32216069)
17. H Zhou 2000 Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers J Clin Pharmacol 40 275 283
18. AH Thomson 1999 Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours Br J Cancer 81 99 107 (Pubitemid 29415498)
19. FDA (2000) Good laboratory practice for nonclinical laboratory studies
20. FDA (2002) Guidance for industry: food-effect bioavailability and fed bioequivalence studies
21. Pinheiro JC, Bates DM (2000) Mixed-effect models in S and S-Plus. Springer, Berlin Heidelberg New York
22. Beal SL, Sheiner LB (1989) NONMEM users guides. Icon Development Solutions, Ellicott City, Maryland, USA
23. D Soy SL Beal LB Sheiner 2004 Population one-compartment pharmacokinetic analysis with missing dosage data Clin Pharmacol Ther 76 441 451 (Pubitemid 39469868)
24. Byon W, Fletcher CV, Brundage RC (2008) Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn 35(1):101-116 (Feb)
25. SL Beal 2001 Ways to fit a PK model with some data below the quantification limit J Pharmacokinet Pharmacodyn 28 481 504 (Pubitemid 33151426)
26. Abramowitz M, Stegun IA (1972) Handbook of mathematical functions. National Bureau of Standards, Washington
27. MO Karlsson RM Savic 2007 Diagnosing model diagnostics Clin Pharmacol Ther 82 17 20 (Pubitemid 46944205)
28. RM Savic DM Jonker T Kerbusch MO Karlsson 2007 Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies J Pharmacokinet Pharmacodyn 34 5 711 726 (Pubitemid 47477040)
29. L Lindbom P Pihlgren EN Jonsson 2005 PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM Comput Methods Programs Biomed 79 241 257 (Pubitemid 41196689)
30. EN Jonsson O Karlsson 1999 Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Methods Programs Biomed 58 51 64 (Pubitemid 29049052)